

**You and a family member or caregiver are cordially invited to join us for  
*Common Connections: An AFSTYLA Story!***

**Friday, June 15, 2018**

**Check-in**

6:30 PM - 7:00 PM

**Presentation**

7:00 PM - 8:00 PM

Hilton Garden Inn North Little Rock  
Pinnacle Ballroom A  
4100 Glover Lane  
North Little Rock, AR 72117

**REGISTER BY PHONE**

**Phone:** 501-428-5754

**Nurse Speaker:**

**Corbett Reinbold, RN, BSN, CCRC**

Blood Center of Wisconsin, Part of Versiti  
Milwaukee, WI

**This program will be in  
conjunction with the  
Hemophilia Foundation of  
Arkansas**

**Patient Advocate Speaker:**

**Hector Grisalez**

Cicero, IL

This program offers you and your family member or caregiver the opportunity to:

- Deepen your understanding of hemophilia
- Learn about the clinical profile of new medication
- Discover valuable resources, tools, and support
- Share experiences, ask questions, and gain valuable information and support from others in the hemophilia community

*Anyone under 18 years of age must be accompanied by a parent or caregiver.*

**Please see Important Safety Information on reverse and  
full prescribing information available at this presentation.**

## Important Safety Information

AFSTYLA is used to treat and control bleeding episodes in people with hemophilia A. Used regularly (prophylaxis), AFSTYLA can reduce the number of bleeding episodes and the risk of joint damage due to bleeding. Your doctor might also give you AFSTYLA before surgical procedures.

AFSTYLA<sup>®</sup>, Antihemophilic Factor (Recombinant), Single Chain, is administered by intravenous injection into the bloodstream, and can be self-administered or administered by a caregiver. Your healthcare provider or hemophilia treatment center will instruct you on how to do an infusion. Carefully follow prescriber instructions regarding dose and infusion schedule, which are based on your weight and the severity of your condition.

Do not use AFSTYLA if you know you are allergic to any of its ingredients, or to hamster proteins. Tell your healthcare provider if you previously had an allergic reaction to any product containing Factor VIII (FVIII), or have been told you have inhibitors to FVIII, as AFSTYLA might not work for you. Inform your healthcare provider of all medical conditions and problems you have, as well as all medications you are taking.

Immediately stop treatment and contact your healthcare provider if you see signs of an allergic reaction, including a rash or hives, itching, tightness of chest or throat, difficulty breathing, lightheadedness, dizziness, nausea, or a decrease in blood pressure.

Your body can make antibodies, called inhibitors, against FVIII, which could stop AFSTYLA from working properly. You might need to be tested for inhibitors from time to time. Contact your healthcare provider if bleeding does not stop after taking AFSTYLA.

In clinical trials, dizziness and allergic reactions were the most common side effects. However, these are not the only side effects possible. Tell your healthcare provider about any side effect that bothers you or does not go away.

**Please see accompanying full prescribing information for AFSTYLA, including patient product information.**

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

Biotherapies for Life<sup>®</sup> **CSL Behring**

AFSTYLA is manufactured by CSL Behring GmbH and distributed by CSL Behring LLC. AFSTYLA<sup>®</sup> is a registered trademark of CSL Behring Recombinant Facility AG. Biotherapies for Life<sup>®</sup> is a registered trademark of CSL Behring LLC.

©2017 CSL Behring LLC. The product information presented on this invitation is intended for US residents only. US-AFS-0027 03/2017

 **AFSTYLA<sup>®</sup>**  
Antihemophilic Factor  
(Recombinant), Single Chain